{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:09:46Z","timestamp":1791947386360,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Excellent Young Talents Plan of Guizhou Medical University","award":["No. 2020-102"],"award-info":[{"award-number":["No. 2020-102"]}]},{"name":"High-level Overseas Talent Fund for Home Work From Ministry of Human Resources and Social Security","award":["No. RSBLXHGZ202001"],"award-info":[{"award-number":["No. RSBLXHGZ202001"]}]},{"name":"Foundation for Training Programs of Innovation and Entrepreneurship for Undergraduates of Guizhou Medical University","award":["No. S202010660015"],"award-info":[{"award-number":["No. S202010660015"]}]},{"name":"distinguished young scholars of nanjing","award":["JQX20008"],"award-info":[{"award-number":["JQX20008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The combination of berberine (BER) and curcumin (CUR) has been verified with ameliorative effects on non-alcohol fatty liver disease (NAFLD). However, discrepant bioavailability and biodistribution of BER and CUR remained an obstacle to achieve synergistic effects. Multilayer nanovesicles have great potential for the protection and oral delivery of drug combinations. Therein lies bile salts inserted liposomes, named as bilosomes, that possesses long residence time in the gastrointestinal tract (GIT) and permeability across the small intestine. Diethylaminoethyl dextran (DEAE-DEX) is generally used as an outside layer on the nanovesicles to increase the mucinous stability and promote oral absorption. Herein, we developed a DEAE-DEX-coated bilosome with BER and CUR encapsulated (DEAE-DEX@LSDBC) for the treatment of NAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>DEAE-DEX@LSDBC with 150\u00a0nm size exhibited enhanced permeation across mucus and Caco-2 monolayer. In vivo pharmacokinetics study demonstrated that DEAE-DEX@LSDBC profoundly prolonged the circulation time and improved the oral absorption of both BER and CUR. Intriguingly, synchronized biodistribution of BER and CUR and highest biodistribution at liver was achieved by DEAE-DEX@LSDBC, which contributed to the optimal ameliorative effects on NAFLD. It was further verified to be mainly mediated by anti-oxidation and anti-inflammation related pathways<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>DEAE-DEX coated bilosome displayed promoted oral absorption, prolonged circulation and synchronized biodistribution of BER and CUR, leading to improved ameliorative effects on NAFLD in mice, which provided a promising strategy for oral administration of drug combinations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphic abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12951-021-00979-1","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T07:02:52Z","timestamp":1628060572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice"],"prefix":"10.1186","volume":"19","author":[{"given":"Yi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runbin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zipeng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangchun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianming","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3351-7124","authenticated-orcid":false,"given":"Jianqing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"key":"979_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"979_CR2","first-page":"CD011640","volume":"3","author":"R Lombardi","year":"2017","unstructured":"Lombardi R, Onali S, Thorburn D, Davidson B, Gurusamy K, Tsochatzis E. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011640.","journal-title":"Cochrane Database Syst Rev"},{"key":"979_CR3","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos M. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69:2672\u201382.","journal-title":"Hepatology"},{"key":"979_CR4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.redox.2018.01.009","volume":"15","author":"A Borrelli","year":"2018","unstructured":"Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, Mancini A. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: current and innovative therapeutic approaches. Redox Biol. 2018;15:467\u201379.","journal-title":"Redox Biol"},{"key":"979_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5604\/16652681.1226814","volume":"16","author":"A Altamirano-Barrera","year":"2017","unstructured":"Altamirano-Barrera A, Barranco-Fragoso B, Mendez-Sanchez N. Management strategies for liver fibrosis. Ann Hepatol. 2017;16:48\u201356.","journal-title":"Ann Hepatol"},{"key":"979_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3390\/cells9010176","volume":"9","author":"S Quesada-V\u00e1zquez","year":"2020","unstructured":"Quesada-V\u00e1zquez S, Aragon\u00e8s G, Del Bas JM, Escot\u00e9 X. Diet, gut microbiota and non-alcoholic fatty liver disease: three parts of the same axis. Cells. 2020;9:176.","journal-title":"Cells"},{"key":"979_CR7","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis E. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038\u201348.","journal-title":"Metabolism"},{"key":"979_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.apsb.2019.11.017","volume":"10","author":"T Yan","year":"2020","unstructured":"Yan T, Yan N, Wang P, Xia Y, Hao H, Wang G, Gonzalez FJ. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B. 2020;10:3\u201318.","journal-title":"Acta Pharm Sin B"},{"key":"979_CR9","doi-asserted-by":"publisher","first-page":"6890","DOI":"10.3748\/wjg.v22.i30.6890","volume":"22","author":"H Yao","year":"2016","unstructured":"Yao H, Qiao YJ, Zhao YL, Tao XF, Xu LN, Yin LH, Qi Y, Peng JY. Herbal medicines and nonalcoholic fatty liver disease. World J Gastroenterol. 2016;22:6890\u2013905.","journal-title":"World J Gastroenterol"},{"key":"979_CR10","doi-asserted-by":"publisher","first-page":"110984","DOI":"10.1016\/j.biopha.2020.110984","volume":"133","author":"X Xu","year":"2021","unstructured":"Xu X, Yi H, Wu J, Kuang T, Zhang J, Li Q, Du H, Xu T, Jiang G, Fan G. Therapeutic effect of berberine on metabolic diseases: both pharmacological data and clinical evidence. Biomed Pharmacother. 2021;133:110984.","journal-title":"Biomed Pharmacother"},{"key":"979_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ejphar.2011.07.036","volume":"668","author":"L Xing","year":"2011","unstructured":"Xing L, Zhang L, Liu T, Hua Y, Zheng P, Ji G. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur J Pharmacol. 2011;668:467\u201371.","journal-title":"Eur J Pharmacol"},{"key":"979_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12967-015-0383-6","volume":"13","author":"X Yuan","year":"2015","unstructured":"Yuan X, Wang J, Tang X, Li Y, Xia P, Gao X. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. J Transl Med. 2015;13:24\u201335.","journal-title":"J Transl Med"},{"key":"979_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fphar.2020.00185","volume":"11","author":"W Mai","year":"2020","unstructured":"Mai W, Xu Y, Xu J, Zhao D, Ye L, Yu G, Wang Z, Lu Q, Lin J, Yang T, et al. Berberine inhibits nod-like receptor family pyrin domain containing 3 inflammasome activation and pyroptosis in nonalcoholic steatohepatitis via the ROS\/TXNIP axis. Front Pharmacol. 2020;11:185\u2013200.","journal-title":"Front Pharmacol"},{"key":"979_CR14","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/molecules21101335","volume":"21","author":"X Zhu","year":"2016","unstructured":"Zhu X, Bian H, Gao X. The potential mechanisms of berberine in the treatment of nonalcoholic fatty liver disease. Molecules. 2016;21:1335\u201348.","journal-title":"Molecules"},{"key":"979_CR15","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2174\/1381612822666161010115235","volume":"23","author":"N Zabihi","year":"2017","unstructured":"Zabihi N, Pirro M, Johnston T, Sahebkar A. Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? The data suggest yes. Curr Pharm Des. 2017;23:969\u201382.","journal-title":"Curr Pharm Des"},{"key":"979_CR16","doi-asserted-by":"publisher","first-page":"e0172900","DOI":"10.1371\/journal.pone.0172900","volume":"12","author":"ME Inzaugarat","year":"2017","unstructured":"Inzaugarat ME, De Matteo E, Baz P, Lucero D, Garcia CC, Gonzalez Ballerga E, Daruich J, Sorda JA, Wald MR, Chernavsky AC. New evidence for the therapeutic potential of curcumin to treat nonalcoholic fatty liver disease in humans. PLoS ONE. 2017;12:e0172900.","journal-title":"PLoS ONE"},{"key":"979_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.biopha.2018.01.071","volume":"99","author":"WW Feng","year":"2018","unstructured":"Feng WW, Kuang SY, Tu C, Ma ZJ, Pang JY, Wang YH, Zang QC, Liu TS, Zhao YL, Xiao XH, Wang JB. Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin. Biomed Pharmacother. 2018;99:325\u201333.","journal-title":"Biomed Pharmacother"},{"key":"979_CR18","first-page":"516","volume":"20","author":"SZK Rad","year":"2017","unstructured":"Rad SZK, Rameshrad M, Hosseinzadeh H. Toxicology effects of berberis vulgaris (barberry) and its active constituent, berberine: a review. Iran J Basic Med Sci. 2017;20:516\u201329.","journal-title":"Iran J Basic Med Sci"},{"key":"979_CR19","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.3390\/ijerph15102093","volume":"15","author":"Y Kim","year":"2018","unstructured":"Kim Y, Clifton P. Curcumin, cardiometabolic health and dementia. Int J Environ Res Public Health. 2018;15:2093\u2013127.","journal-title":"Int J Environ Res Public Health"},{"key":"979_CR20","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1021\/acs.jmedchem.6b00975","volume":"60","author":"KM Nelson","year":"2017","unstructured":"Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60:1620\u201337.","journal-title":"J Med Chem"},{"key":"979_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/molecules24010103","volume":"24","author":"HX Cui","year":"2018","unstructured":"Cui HX, Hu YN, Li JW, Yuan K, Guo Y. Preparation and evaluation of antidiabetic agents of berberine organic acid salts for enhancing the bioavailability. Molecules. 2018;24:103\u201312.","journal-title":"Molecules"},{"key":"979_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jconrel.2014.05.036","volume":"187","author":"C Dawidczyk","year":"2014","unstructured":"Dawidczyk C, Kim C, Park J, Russell L, Lee K, Pomper M, Searson P. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release. 2014;187:133\u201344.","journal-title":"J Control Release"},{"key":"979_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.biomaterials.2018.03.004","volume":"166","author":"W Tang","year":"2018","unstructured":"Tang W, Tang W, Szeitz A, Kulkarni J, Cullis P, Li S. Systemic study of solvent-assisted active loading of gambogic acid into liposomes and its formulation optimization for improved delivery. Biomaterials. 2018;166:13\u201326.","journal-title":"Biomaterials"},{"key":"979_CR24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ijpharm.2019.04.069","volume":"564","author":"Y Elnaggar","year":"2019","unstructured":"Elnaggar Y, Omran S, Hazzah H, Abdallah O. Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronate. Int J Pharm. 2019;564:410\u201325.","journal-title":"Int J Pharm"},{"key":"979_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.colsurfb.2018.07.022","volume":"171","author":"D Li","year":"2018","unstructured":"Li D, Zhuang J, Yang Y, Wang D, Yang J, He H, Fan W, Banerjee A, Lu Y, Wu W, et al. Loss of integrity of doxorubicin liposomes during transcellular transportation evidenced by fluorescence resonance energy transfer effect. Colloids Surf B Biointerfaces. 2018;171:224\u201332.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"979_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ijpharm.2012.10.025","volume":"441","author":"S Hu","year":"2013","unstructured":"Hu S, Niu M, Hu F, Lu Y, Qi J, Yin Z, Wu W. Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media. Int J Pharm. 2013;441:693\u2013700.","journal-title":"Int J Pharm"},{"key":"979_CR27","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.3109\/10717544.2014.956240","volume":"23","author":"M Aburahma","year":"2016","unstructured":"Aburahma M. Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide\/protein-based therapeutics or vaccines. Drug Deliv. 2016;23:1847\u201367.","journal-title":"Drug Deliv"},{"key":"979_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijpharm.2013.11.028","volume":"460","author":"M Niu","year":"2014","unstructured":"Niu M, Tan Y, Guan P, Hovgaard L, Lu Y, Qi J, Lian R, Li X, Wu W. Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study. Int J Pharm. 2014;460:119\u201330.","journal-title":"Int J Pharm"},{"key":"979_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","volume":"203","author":"A D'Souza","year":"2015","unstructured":"D\u2019Souza A, Devarajan P. Asialoglycoprotein receptor mediated hepatocyte targeting\u2014strategies and applications. J Control Release. 2015;203:126\u201339.","journal-title":"J Control Release"},{"key":"979_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0169-409X(01)00209-5","volume":"52","author":"M Hashida","year":"2001","unstructured":"Hashida M, Nishikawa M, Yamashita F, Takakura Y. Cell-specific delivery of genes with glycosylated carriers. Adv Drug Deliv Rev. 2001;52:187\u201396.","journal-title":"Adv Drug Deliv Rev"},{"key":"979_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2013.04.002","volume":"449","author":"D Chen","year":"2013","unstructured":"Chen D, Xia D, Li X, Zhu Q, Yu H, Zhu C, Gan Y. Comparative study of Pluronic(\u00ae) F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats. Int J Pharm. 2013;449:1\u20139.","journal-title":"Int J Pharm"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-021-00979-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-021-00979-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-021-00979-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T07:04:14Z","timestamp":1628060654000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-021-00979-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["979"],"URL":"https:\/\/doi.org\/10.1186\/s12951-021-00979-1","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,4]]},"assertion":[{"value":"1 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the animal experiments were conducted according to the National Institutes of Health Guide for the Care and use of Laboratory Animals and were strictly complied with protocols approved by the Animal Care Welfare Committee (ACWC, Guizhou Medical University, No. 2000108). Consent to participate: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}